Compare VELO & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VELO | PRTA |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.0M | 449.7M |
| IPO Year | 2020 | 2013 |
| Metric | VELO | PRTA |
|---|---|---|
| Price | $12.50 | $9.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $18.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.7M | 438.3K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.96 | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | ★ $45,973,000.00 | $814,000.00 |
| Revenue This Year | $42.22 | $1,111.38 |
| Revenue Next Year | $50.08 | N/A |
| P/E Ratio | ★ N/A | $36.12 |
| Revenue Growth | ★ 12.12 | N/A |
| 52 Week Low | $2.87 | $7.73 |
| 52 Week High | $31.75 | $11.80 |
| Indicator | VELO | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 59.12 |
| Support Level | $12.06 | $8.91 |
| Resistance Level | $15.92 | $10.29 |
| Average True Range (ATR) | 1.33 | 0.42 |
| MACD | 0.05 | 0.08 |
| Stochastic Oscillator | 7.43 | 93.92 |
Velo3D Inc provides additive manufacturing (AM), also referred to as three-dimensional printing (3D printing), to deliver breakthroughs in performance, cost, and time in the production of high-value metal parts. The Velo3D intelligent metal additive manufacturing solution is comprised of the Velo3D Flow intelligent print preparation software, the Sapphire production system, and Velo3D Assure, real-time quality assurance software. Its complete manufacturing solution enables clients to build the parts needed, speed their development, and reduce their product costs.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.